Petefészekrák: vizsgálatok itt: Kanada
56 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Calgary, Greater Sudbury, Mississauga, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 1/2. fázisTaking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Chicoutimi, Montreal
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Montreal, Sherbrooke, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - No phaseTaking peopleA Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Where
- Montreal, Vancouver
- Életkor
- 35 év to 50 év
- People
- 1956 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT04251052 - 2. fázisTaking peopleInvestigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Where
- Greenfield Park, Montreal, Québec, Toronto, Winnipeg
- Életkor
- 18 év and over
- People
- 397 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06787612 · EU 2024-517806-27-00 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 2. fázisTaking peopleImmunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
- Where
- Kelowna, Montreal, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Canadian Cancer Trials Group
See details and how to joinNCT04918186 - 3. fázisTaking peopleEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Where
- Barrie, Kitchener, London, Montreal, Oakville, Oshawa, Québec, Regina, Saskatoon, Sherbrooke, Toronto
- Életkor
- 18 év to 60 év
- People
- 3960 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05879926 - 2. fázisTaking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Halifax, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - 3. fázisTaking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Calgary, Hamilton, Montreal, Sherbrooke, Surrey, Toronto
- Életkor
- 18 év and over
- People
- 1630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - 3. fázisTaking peopleMo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 720 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00 - 3. fázisTaking peopleA Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Where
- Montreal, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00 - No phaseTaking peopleMainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 180
- Run by
- Unity Health Toronto
See details and how to joinNCT07387263 - 2/3. fázisTaking peopleA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Calgary, London, Montreal, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Edmonton, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1. fázisTaking peopleAnti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Where
- Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 138 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07360314 · EU 2025-523232-39-00 - 3. fázisTaking peopleTorvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Where
- Abbotsford British Columbia, Montreal
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07816666 · EU 2026-526776-23-00 - 3. fázisTaking peopleStudy to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Where
- Calgary, Edmonton, London, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 466 worldwide
- Run by
- Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00 - 1/2. fázisTaking peopleA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Where
- Calgary, Montreal, Ottawa, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01 - No phaseTaking peopleCfDNA in Hereditary And High-risk Malignancies 2
- Where
- Halifax, Montreal, St. John's, Toronto, Vancouver
- Életkor
- Up to 90 év
- People
- 1000
- Run by
- University Health Network, Toronto
See details and how to joinNCT06726642 - 1. fázisTaking peopleStudy of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 473 worldwide
- Run by
- Bicara Therapeutics
See details and how to joinNCT04429542 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Edmonton, London, Montreal, Toronto
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 3. fázisTaking peopleA Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 690 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07684612 · EU 2025-523366-24-00